{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T03:40:18Z","timestamp":1790394018766,"version":"4.1.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"22","license":[{"start":{"date-parts":[[2020,4,20]],"date-time":"2020-04-20T00:00:00Z","timestamp":1587340800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,4,20]],"date-time":"2020-04-20T00:00:00Z","timestamp":1587340800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002920","name":"Research Grants Council, University Grants Committee","doi-asserted-by":"publisher","award":["CUHK 14100019"],"award-info":[{"award-number":["CUHK 14100019"]}],"id":[{"id":"10.13039\/501100002920","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002920","name":"Research Grants Council, University Grants Committee","doi-asserted-by":"publisher","award":["CUHK 14118518"],"award-info":[{"award-number":["CUHK 14118518"]}],"id":[{"id":"10.13039\/501100002920","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010428","name":"Innovation and Technology Fund","doi-asserted-by":"publisher","award":["ITS\/068\/18, PiH\/009\/19, PiH\/010\/19, InP\/008\/19, InP\/009\/19"],"award-info":[{"award-number":["ITS\/068\/18, PiH\/009\/19, PiH\/010\/19, InP\/008\/19, InP\/009\/19"]}],"id":[{"id":"10.13039\/501100010428","id-type":"DOI","asserted-by":"publisher"}]},{"name":"CUHK Direct Grant for Research"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2020,5,28]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Hippo signaling functions to limit cellular growth, but the aberrant nuclear accumulation of its downstream YAP1 leads to carcinogenesis. YAP1\/TEAD complex activates the oncogenic downstream transcription, such as CTGF and c-Myc. How YAP1 is protected in the cytoplasm from ubiquitin-mediated degradation remains elusive. In this study, a member of Angiomotin (Motin) family, AMOTL1 (Angiomotin Like 1), was screened out as the only one to promote YAP1 nuclear accumulation by several clinical cohorts, which was further confirmed by the cellular functional assays. The interaction between YAP1 and AMOTL1 was suggested by co-immunoprecipitation and immunofluorescent staining. The clinical significance of the AMOTL1\u2013YAP1\u2013CTGF axis in gastric cancer (GC) was analyzed by multiple clinical cohorts. Moreover, the therapeutic effect of targeting the oncogenic axis was appraised by drug-sensitivity tests and xenograft-formation assays. The upregulation of AMOTL1 is associated with unfavorable clinical outcomes of GC, and knocking down AMOTL1 impairs its oncogenic properties. The cytoplasmic interaction between AMOTL1 and YAP1 protects each other from ubiquitin-mediated degradation. AMOTL1 promotes YAP1 translocation into the nuclei to activate the downstream expression, such as CTGF. Knocking down AMOTL1, YAP1, and CTGF enhances the therapeutic efficacies of the first-line anticancer drugs. Taken together, AMOTL1 plays an oncogenic role in gastric carcinogenesis through interacting with YAP1 and promoting its nuclear accumulation. A combination of AMOTL1, YAP1, and CTGF expression might serve as a surrogate of Hippo activation status. The co-activation of the AMOTL1\/YAP1\u2013CTGF axis is associated with poor clinical outcomes of GC patients, and targeting this oncogenic axis may enhance the chemotherapeutic effects.<\/jats:p>","DOI":"10.1038\/s41388-020-1293-5","type":"journal-article","created":{"date-parts":[[2020,4,20]],"date-time":"2020-04-20T13:04:20Z","timestamp":1587387860000},"page":"4375-4389","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["AMOTL1 enhances YAP1 stability and promotes YAP1-driven gastric oncogenesis"],"prefix":"10.1038","volume":"39","author":[{"given":"Yuhang","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinglin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi Chun","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Man","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuoqing","family":"Weng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfred S. L.","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3488-6124","authenticated-orcid":false,"given":"Kwok Wai","family":"Lo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick M. K.","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4651-677X","authenticated-orcid":false,"given":"Wei","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ka Fai","family":"To","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,20]]},"reference":[{"key":"1293_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394\u2013424.","journal-title":"CA Cancer J Clin"},{"key":"1293_CR2","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1056\/NEJMoa001999","volume":"345","author":"N Uemura","year":"2001","unstructured":"Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, et al. Helicobacter pylori infection and the development of gastric cancer. N. Engl J Med. 2001;345:784\u20139.","journal-title":"N. Engl J Med"},{"key":"1293_CR3","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1136\/gutjnl-2011-301839","volume":"61","author":"N Deng","year":"2012","unstructured":"Deng N, Goh LK, Wang H, Das K, Tao J, Tan IB, et al. A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. Gut. 2012;61:673\u201384.","journal-title":"Gut"},{"key":"1293_CR4","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nature13480","volume":"513","author":"Cancer Genome Atlas Research N.","year":"2014","unstructured":"Cancer Genome Atlas Research N. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513:202\u20139.","journal-title":"Nature"},{"key":"1293_CR5","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.cell.2018.03.035","volume":"173","author":"F Sanchez-Vega","year":"2018","unstructured":"Sanchez-Vega F, Mina M, Armenia J, Chatila WK, Luna A, La KC, et al. Oncogenic signaling pathways in The Cancer Genome Atlas. Cell. 2018;173:321\u201337. e310.","journal-title":"Cell"},{"key":"1293_CR6","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.21037\/jtd.2017.06.26","volume":"9","author":"W Kang","year":"2017","unstructured":"Kang W, Zhou Y, To KF. The large tumor suppressor family: friend or foe? J Thorac Dis. 2017;9:1748\u201351.","journal-title":"J Thorac Dis"},{"key":"1293_CR7","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.canlet.2018.04.004","volume":"426","author":"Y Zhou","year":"2018","unstructured":"Zhou Y, Huang T, Zhang J, Cheng ASL, Yu J, Kang W, et al. Emerging roles of Hippo signaling in inflammation and YAP-driven tumor immunity. Cancer Lett. 2018;426:73\u20139.","journal-title":"Cancer Lett"},{"key":"1293_CR8","doi-asserted-by":"publisher","first-page":"138","DOI":"10.3390\/ijms17010138","volume":"17","author":"Y Zhou","year":"2016","unstructured":"Zhou Y, Huang T, Cheng AS, Yu J, Kang W, To KF. The TEAD family and its oncogenic role in promoting tumorigenesis. Int J Mol Sci. 2016;17:138.","journal-title":"Int J Mol Sci"},{"key":"1293_CR9","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1101\/gad.192856.112","volume":"26","author":"Y Liu-Chittenden","year":"2012","unstructured":"Liu-Chittenden Y, Huang B, Shim JS, Chen Q, Lee SJ, Anders RA, et al. Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP. Genes Dev. 2012;26:1300\u20135.","journal-title":"Genes Dev"},{"key":"1293_CR10","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.1158\/1078-0432.CCR-10-2467","volume":"17","author":"W Kang","year":"2011","unstructured":"Kang W, Tong JH, Chan AW, Lee TL, Lung RW, Leung PP, et al. Yes-associated protein 1 exhibits oncogenic property in gastric cancer and its nuclear accumulation associates with poor prognosis. Clin Cancer Res. 2011;17:2130\u20139.","journal-title":"Clin Cancer Res"},{"key":"1293_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-015-0323-3","volume":"14","author":"W Kang","year":"2015","unstructured":"Kang W, Tong JH, Lung RW, Dong Y, Zhao J, Liang Q, et al. Targeting of YAP1 by microRNA-15a and microRNA-16-1 exerts tumor suppressor function in gastric adenocarcinoma. Mol Cancer. 2015;14:52.","journal-title":"Mol Cancer"},{"key":"1293_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-017-0134-0","volume":"9","author":"W Kang","year":"2018","unstructured":"Kang W, Huang T, Zhou Y, Zhang J, Lung RWM, Tong JHM, et al. miR-375 is involved in Hippo pathway by targeting YAP1\/TEAD4-CTGF axis in gastric carcinogenesis. Cell Death Dis. 2018;9:92.","journal-title":"Cell Death Dis"},{"key":"1293_CR13","doi-asserted-by":"publisher","first-page":"6518","DOI":"10.1038\/onc.2017.257","volume":"36","author":"Y Zhou","year":"2017","unstructured":"Zhou Y, Huang T, Zhang J, Wong CC, Zhang B, Dong Y, et al. TEAD1\/4 exerts oncogenic role and is negatively regulated by miR-4269 in gastric tumorigenesis. Oncogene. 2017;36:6518\u201330.","journal-title":"Oncogene"},{"key":"1293_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-018-1466-y","volume":"16","author":"T Huang","year":"2018","unstructured":"Huang T, Zhou Y, Zhang J, Cheng ASL, Yu J, To KF, et al. The physiological role of Motin family and its dysregulation in tumorigenesis. J Transl Med. 2018;16:98.","journal-title":"J Transl Med"},{"key":"1293_CR15","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1101\/gad.2000111","volume":"25","author":"B Zhao","year":"2011","unstructured":"Zhao B, Li L, Lu Q, Wang LH, Liu CY, Lei Q, et al. Angiomotin is a novel Hippo pathway component that inhibits YAP oncoprotein. Genes Dev. 2011;25:51\u201363.","journal-title":"Genes Dev"},{"key":"1293_CR16","doi-asserted-by":"publisher","first-page":"4364","DOI":"10.1074\/jbc.C110.205401","volume":"286","author":"W Wang","year":"2011","unstructured":"Wang W, Huang J, Chen J. Angiomotin-like proteins associate with and negatively regulate YAP1. J Biol Chem. 2011;286:4364\u201370.","journal-title":"J Biol Chem"},{"key":"1293_CR17","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1101\/gad.1843810","volume":"24","author":"B Zhao","year":"2010","unstructured":"Zhao B, Li L, Tumaneng K, Wang CY, Guan KL. A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCF(beta-TRCP). Genes Dev. 2010;24:72\u201385.","journal-title":"Genes Dev"},{"key":"1293_CR18","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1016\/j.jhep.2014.06.033","volume":"61","author":"A Perra","year":"2014","unstructured":"Perra A, Kowalik MA, Ghiso E, Ledda-Columbano GM, Di Tommaso L, Angioni MM, et al. YAP activation is an early event and a potential therapeutic target in liver cancer development. J Hepatol. 2014;61:1088\u201396.","journal-title":"J Hepatol"},{"key":"1293_CR19","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.neo.2015.11.010","volume":"18","author":"C Couderc","year":"2016","unstructured":"Couderc C, Boin A, Fuhrmann L, Vincent-Salomon A, Mandati V, Kieffer Y, et al. AMOTL1 promotes breast cancer progression and is antagonized by Merlin. Neoplasia. 2016;18:10\u201324.","journal-title":"Neoplasia"},{"key":"1293_CR20","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.canlet.2018.02.015","volume":"423","author":"T Lu","year":"2018","unstructured":"Lu T, Li Z, Yang Y, Ji W, Yu Y, Niu X, et al. The Hippo\/YAP1 pathway interacts with FGFR1 signaling to maintain stemness in lung cancer. Cancer Lett. 2018;423:36\u201346.","journal-title":"Cancer Lett"},{"key":"1293_CR21","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1093\/carcin\/bgt409","volume":"35","author":"B Lim","year":"2014","unstructured":"Lim B, Park JL, Kim HJ, Park YK, Kim JH, Sohn HA, et al. Integrative genomics analysis reveals the multilevel dysregulation and oncogenic characteristics of TEAD4 in gastric cancer. Carcinogenesis. 2014;35:1020\u20137.","journal-title":"Carcinogenesis"},{"key":"1293_CR22","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.3748\/wjg.v22.i3.1279","volume":"22","author":"W Kang","year":"2016","unstructured":"Kang W, Cheng AS, Yu J, To KF. Emerging role of Hippo pathway in gastric and other gastrointestinal cancers. World J Gastroenterol. 2016;22:1279\u201388.","journal-title":"World J Gastroenterol"},{"key":"1293_CR23","doi-asserted-by":"publisher","first-page":"4362","DOI":"10.1038\/onc.2017.24","volume":"36","author":"Z Shi","year":"2017","unstructured":"Shi Z, He F, Chen M, Hua L, Wang W, Jiao S, et al. DNA-binding mechanism of the Hippo pathway transcription factor TEAD4. Oncogene. 2017;36:4362\u20139.","journal-title":"Oncogene"},{"key":"1293_CR24","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1101\/gad.432007","volume":"21","author":"K Aase","year":"2007","unstructured":"Aase K, Ernkvist M, Ebarasi L, Jakobsson L, Majumdar A, Yi C, et al. Angiomotin regulates endothelial cell migration during embryonic angiogenesis. Genes Dev. 2007;21:2055\u201368.","journal-title":"Genes Dev"},{"key":"1293_CR25","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1161\/CIRCRESAHA.109.195156","volume":"105","author":"Y Zheng","year":"2009","unstructured":"Zheng Y, Vertuani S, Nystrom S, Audebert S, Meijer I, Tegnebratt T, et al. Angiomotin-like protein 1 controls endothelial polarity and junction stability during sprouting angiogenesis. Circ Res. 2009;105:260\u201370.","journal-title":"Circ Res"},{"key":"1293_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms4743","volume":"5","author":"S Hultin","year":"2014","unstructured":"Hultin S, Zheng Y, Mojallal M, Vertuani S, Gentili C, Balland M, et al. AmotL2 links VE-cadherin to contractile actin fibres necessary for aortic lumen expansion. Nat Commun. 2014;5:3743.","journal-title":"Nat Commun"},{"key":"1293_CR27","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1242\/dev.02782","volume":"134","author":"H Huang","year":"2007","unstructured":"Huang H, Lu FI, Jia S, Meng S, Cao Y, Wang Y, et al. Amotl2 is essential for cell movements in zebrafish embryo and regulates c-Src translocation. Development. 2007;134:979\u201388.","journal-title":"Development"},{"key":"1293_CR28","doi-asserted-by":"publisher","first-page":"13005","DOI":"10.1074\/jbc.M112.347419","volume":"287","author":"Z Li","year":"2012","unstructured":"Li Z, Wang Y, Zhang M, Xu P, Huang H, Wu D, et al. The Amotl2 gene inhibits Wnt\/beta-catenin signaling and regulates embryonic development in zebrafish. J Biol Chem. 2012;287:13005\u201315.","journal-title":"J Biol Chem"},{"key":"1293_CR29","doi-asserted-by":"publisher","first-page":"ra77","DOI":"10.1126\/scisignal.2004060","volume":"6","author":"C Yi","year":"2013","unstructured":"Yi C, Shen Z, Stemmer-Rachamimov A, Dawany N, Troutman S, Showe LC, et al. The p130 isoform of angiomotin is required for Yap-mediated hepatic epithelial cell proliferation and tumorigenesis. Sci Signal. 2013;6:ra77.","journal-title":"Sci Signal"},{"key":"1293_CR30","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1038\/onc.2016.224","volume":"36","author":"Y Wang","year":"2017","unstructured":"Wang Y, Justilien V, Brennan KI, Jamieson L, Murray NR, Fields AP. PKCiota regulates nuclear YAP1 localization and ovarian cancer tumorigenesis. Oncogene. 2017;36:534\u201345.","journal-title":"Oncogene"},{"key":"1293_CR31","doi-asserted-by":"publisher","first-page":"3725","DOI":"10.1091\/mbc.e11-04-0300","volume":"22","author":"M Paramasivam","year":"2011","unstructured":"Paramasivam M, Sarkeshik A, Yates JR 3rd, Fernandes MJ, McCollum D. Angiomotin family proteins are novel activators of the LATS2 kinase tumor suppressor. Mol Biol Cell. 2011;22:3725\u201333.","journal-title":"Mol Biol Cell"},{"key":"1293_CR32","doi-asserted-by":"publisher","first-page":"4056","DOI":"10.1038\/onc.2014.333","volume":"34","author":"YL Hsu","year":"2015","unstructured":"Hsu YL, Hung JY, Chou SH, Huang MS, Tsai MJ, Lin YS, et al. Angiomotin decreases lung cancer progression by sequestering oncogenic YAP\/TAZ and decreasing Cyr61 expression. Oncogene. 2015;34:4056\u201368.","journal-title":"Oncogene"},{"key":"1293_CR33","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1111\/apm.12750","volume":"125","author":"SA Hong","year":"2017","unstructured":"Hong SA, Son MW, Cho J, Jang SH, Lee HJ, Lee JH, et al. Low angiomotin-p130 with concomitant high Yes-associated protein 1 expression is associated with adverse prognosis of advanced gastric cancer. APMIS. 2017;125:996\u20131006.","journal-title":"APMIS"},{"key":"1293_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-10-122","volume":"10","author":"CG Jiang","year":"2011","unstructured":"Jiang CG, Lv L, Liu FR, Wang ZN, Liu FN, Li YS, et al. Downregulation of connective tissue growth factor inhibits the growth and invasion of gastric cancer cells and attenuates peritoneal dissemination. Mol Cancer. 2011;10:122.","journal-title":"Mol Cancer"},{"key":"1293_CR35","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.3748\/wjg.v20.i7.1694","volume":"20","author":"TY Cheng","year":"2014","unstructured":"Cheng TY, Wu MS, Hua KT, Kuo ML, Lin MT. Cyr61\/CTGF\/Nov family proteins in gastric carcinogenesis. World J Gastroenterol. 2014;20:1694\u2013700.","journal-title":"World J Gastroenterol"},{"key":"1293_CR36","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/nrd4161","volume":"13","author":"R Johnson","year":"2014","unstructured":"Johnson R, Halder G. The two faces of Hippo: targeting the Hippo pathway for regenerative medicine and cancer treatment. Nat Rev Drug Disco. 2014;13:63\u201379.","journal-title":"Nat Rev Drug Disco"},{"key":"1293_CR37","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1053\/j.gastro.2017.02.018","volume":"152","author":"SME Weiler","year":"2017","unstructured":"Weiler SME, Pinna F, Wolf T, Lutz T, Geldiyev A, Sticht C, et al. Induction of chromosome instability by activation of Yes-associated protein and forkhead Box M1 in liver cancer. Gastroenterology. 2017;152:2037\u201351. e2022.","journal-title":"Gastroenterology"},{"key":"1293_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-018-0515-z","volume":"9","author":"M Yu","year":"2018","unstructured":"Yu M, Chen Y, Li X, Yang R, Zhang L, Huangfu L, et al. YAP1 contributes to NSCLC invasion and migration by promoting Slug transcription via the transcription co-factor TEAD. Cell Death Dis. 2018;9:464.","journal-title":"Cell Death Dis"},{"key":"1293_CR39","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201809889","volume":"11","author":"M Trautmann","year":"2019","unstructured":"Trautmann M, Cheng YY, Jensen P, Azoitei N, Brunner I, Hullein J, et al. Requirement for YAP1 signaling in myxoid liposarcoma. EMBO Mol Med. 2019;11:e9889.","journal-title":"EMBO Mol Med"},{"key":"1293_CR40","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-017-0647-2","volume":"16","author":"Y Zhou","year":"2017","unstructured":"Zhou Y, Huang T, Siu HL, Wong CC, Dong Y, Wu F, et al. IGF2BP3 functions as a potential oncogene and is a crucial target of miR-34a in gastric carcinogenesis. Mol Cancer. 2017;16:77.","journal-title":"Mol Cancer"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41388-020-1293-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41388-020-1293-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41388-020-1293-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:20:56Z","timestamp":1684617656000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41388-020-1293-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,20]]},"references-count":40,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2020,5,28]]}},"alternative-id":["1293"],"URL":"https:\/\/doi.org\/10.1038\/s41388-020-1293-5","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,20]]},"assertion":[{"value":"20 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}